Evidence Hub

Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine

Fisher M

AIDS (London, England), 1998

Abstract

This paper reviews the results of three trials, HIV NAT002, AI455-053, and AIDS Clinical Trials Group (ACTG) 306, all of which evaluated the effectiveness of stavudine (d4T)-containing two-nucleoside combinations in antiretroviral-naive patients with human immunodeficiency virus type 1 (HIV-1) infection. The latter two studies directly compared d4T plus didanosine (ddI) or lamivudine (3TC) versus zidovudine (ZDV) plus each of these two nucleosides. The combined results of the three trials support the conclusion that d4T can be used effectively in combination with either ddI or 3TC to reduce viral loads and increase CD4 cell counts in patients with HIV-1 infection. The results of AI455-053 and ACTG 306 show further that combination of d4T with either ddI or 3TC is at least as effective as the use of ZDV with these nucleosides.

How strong is the evidence?

Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free